SER
Serina Therapeutics, Inc.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Last price
2.80
▲ 0.15 (5.66%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.65
Prev close
2.65
Day high
2.87
Day low
2.63
Volume
46.00K
Market cap
$72.90M
P/E (TTM)
—
52W range
1.22 – 7.92
Day trading desk
Gap from prior close
-0.00%
Prior close 2.65
VWAP
2.79
+0.37% from price
Relative volume
0.57×
Quiet session
Session range
9.62%
2.62 – 2.87
Position in range
72%
Near session high
ATR (14D)
0.22
7.78% of price
Prior day high
2.69
PDH
Prior day low
2.56
PDL
Bid / ask spread
—
Quote not published
Session volume
46.18K
Avg 81.67K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.50%
+3.9%
1M
+37.32%
+33.6%
3M
+52.09%
+49.0%
6M
+77.16%
+66.1%
YTD
+50.03%
+37.7%
1Y
-44.81%
-64.8%
3Y
-90.33%
-164.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SER open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+8.78M
Net buying
Buy transactions
12
8.83M shares
Sell transactions
2
45.50K shares
Net transactions
+14
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
12.89M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 7, 26 | BRANNAN STEPHEN K Director |
BUY | 1.00K | $2.03K | Direct |
| Jun 17, 26 | VENKATESAN JAY R Director |
CONVERSION | 224.15K | $504.34K | Indirect |
| Jun 17, 26 | BAILEY GREGORY HUGH Director |
CONVERSION | 8.44M | $18.98M | Direct |
| Jun 12, 26 | WILSON KAREN J Director |
BUY | 10.10K | $17.75K | Direct |
| May 26, 26 | LEDGER STEVEN A Chief Executive Officer |
STOCK | 10.10K | $19.49K | Direct |
| May 22, 26 | WILSON KAREN J Director |
BUY | 20.00K | $37.00K | Direct |
| May 22, 26 | VENKATESAN JAY R Director |
BUY | 589 | $1.05K | Direct |
| May 19, 26 | MARSHALL RICHARD PETER M.D., PH.D. Director |
BUY | 12.18K | $20.10K | Direct |
| Mar 31, 26 | BAILEY GREGORY HUGH Director |
STOCK | 59.67K | $115.75K | Direct |
| Mar 31, 26 | VENKATESAN JAY R Director |
STOCK | 7.55K | $14.65K | Direct |
| Mar 23, 26 | MOREADITH RANDALL W. Officer |
SELL | 6.50K | $18.57K | Direct |
| Mar 23, 26 | MOREADITH RANDALL W. Officer |
CONVERSION | 6.50K | $390 | Direct |
| Mar 19, 26 | MOREADITH RANDALL W. Officer |
SELL | 39.00K | $97.50K | Direct |
| Mar 19, 26 | MOREADITH RANDALL W. Officer |
CONVERSION | 39.00K | $2.34K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAILEY GREGORY HUGH |
Director | 8.56M | Conversion of Exercise of derivative security |
BRANNAN STEPHEN K |
Director | 1.00K | Purchase |
JUVENESCENCE LTD. |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
LEDGER STEVEN A |
Chief Executive Officer | 10.10K | Stock Award(Grant) |
MARSHALL RICHARD PETER M.D., PH.D. |
Director | 12.18K | Purchase |
MINTZ STEVEN MICHAEL |
Director | — | Purchase |
MOREADITH RANDALL W. |
Officer | 0 | Sale |
VENKATESAN JAY R |
Director | — | Conversion of Exercise of derivative security |
WILSON KAREN J |
Director | 10.10K | Purchase |
Fundamentals
Market cap$72.90M
Enterprise value$53.63M
Revenue (TTM)$0
Gross profit$-14.07M
EBITDA$-25.59M
Net income$-23.93M
EPS (TTM)$-1.87
Free cash flow$-12.35M
Total cash$23.02M
Total debt$3.75M
Book value / share$0.85
Shares outstanding25.40M
Float11.15M
Short % of float1.94%
Dividend yield—
Beta (5Y)-0.00
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.73
PEG ratio—
Price / sales—
Price / book3.37
EV / revenue—
EV / EBITDA-2.10
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-207.94%
Return on assets-92.30%
Debt / equity20.04
Current ratio6.65
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $3.00M | $500.00K | — |
| Operating revenue | $0 | $0 | $3.00M | $500.00K | — |
| Research & development | $13.15M | $7.48M | $2.39M | $1.57M | +75.9% |
| Selling, general & admin | $11.00M | $9.62M | $3.89M | $1.29M | +14.3% |
| Total operating expense | $24.02M | $17.05M | $6.13M | $2.77M | +40.9% |
| Operating income | -$24.02M | -$17.05M | -$3.13M | -$2.27M | -40.9% |
| Net interest income | -$213.00K | -$526.00K | -$558.00K | -$14.12K | +59.5% |
| Pre-tax income | -$19.20M | -$11.21M | $5.27M | -$2.68M | -71.3% |
| Tax provision | $18.00K | — | — | — | — |
| Net income | -$19.18M | -$11.14M | $5.27M | -$2.68M | -72.2% |
| Net income to common | -$19.18M | -$11.14M | $5.27M | -$2.68M | -72.2% |
| Basic EPS | -1.91 | -1.51 | 0.63 | -1.23 | -26.5% |
| Diluted EPS | -1.91 | -1.51 | 0.63 | -1.23 | -26.5% |
| EBIT | -$18.98M | -$10.68M | $5.83M | -$2.67M | -77.7% |
| EBITDA | -$18.91M | -$10.49M | $5.92M | -$2.60M | -80.3% |
| Basic shares | 10.19M | 7.36M | 8.41M | 2.18M | +38.5% |
| Diluted shares | 10.19M | 7.36M | 8.41M | 7.55M | +38.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.06M | $3.67M | $7.62M | $532.23K | — | -16.8% |
| Cash & short-term investments | $4.78M | $3.67M | $7.62M | $532.23K | — | +30.1% |
| Accounts receivable | — | — | — | $0 | $1.11K | — |
| Total current assets | $6.08M | $5.68M | $7.62M | $548.58K | — | +7.1% |
| Property, plant & equipment | $842.00K | $1.05M | $1.35M | $309.47K | — | -19.7% |
| Total assets | $6.95M | $6.72M | $8.97M | $858.04K | — | +3.4% |
| Total current liabilities | $3.56M | $2.37M | $1.41M | $437.69K | — | +50.6% |
| Long-term debt | $2.95M | — | $2.98M | $1.62M | — | — |
| Total debt | $3.14M | $268.00K | $3.44M | $1.81M | — | +1,072.4% |
| Total liabilities | $6.99M | $6.22M | $41.26M | $38.64M | — | +12.4% |
| Retained earnings | -$63.50M | -$44.32M | -$33.18M | -$38.45M | — | -43.3% |
| Shareholder equity | -$37.00K | $641.00K | -$32.29M | -$37.78M | — | -105.8% |
| Working capital | $2.52M | $3.31M | $6.21M | $110.89K | — | -24.0% |
| Net tangible assets | -$37.00K | $641.00K | -$32.29M | -$37.78M | — | -105.8% |
| Shares issued | 10.77M | 9.42M | 8.41M | 8.41M | — | +14.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$19.21M | -$11.21M | $5.27M | -$2.68M | -71.5% |
| Depreciation & amortisation | $73.00K | $194.00K | $90.00K | $61.27K | -62.4% |
| Stock-based compensation | $3.79M | $2.60M | $25.00K | $7.11K | +46.2% |
| Change in working capital | $1.47M | -$3.32M | $81.00K | -$11.94K | +144.3% |
| Operating cash flow | -$17.95M | -$17.14M | -$2.48M | -$2.08M | -4.8% |
| Capital expenditure | -$59.00K | -$22.00K | -$504.00K | -$9.68K | -168.2% |
| Investing cash flow | -$59.00K | -$22.00K | -$504.00K | $980.94K | -168.2% |
| Financing cash flow | $17.41M | $13.21M | $10.07M | $1.31M | +31.8% |
| Free cash flow | -$18.01M | -$17.16M | -$2.98M | -$2.09M | -5.0% |
| End cash position | $3.06M | $3.67M | $7.62M | $532.23K | -16.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $3.20M | $3.40M | $3.65M | $3.15M | $2.95M | -5.9% |
| Selling, general & admin | $3.08M | $2.81M | $2.74M | $2.54M | $2.91M | +9.8% |
| Total operating expense | $6.28M | $6.21M | $6.39M | $5.57M | $5.86M | +1.2% |
| Operating income | -$6.28M | -$6.21M | -$6.39M | -$5.57M | -$5.86M | -1.2% |
| Net interest income | -$189.00K | -$198.00K | -$6.00K | -$9.00K | $0 | +4.5% |
| Pre-tax income | -$6.89M | -$3.32M | -$4.59M | -$6.46M | -$4.82M | -107.7% |
| Tax provision | $7.00K | — | — | — | $0 | — |
| Net income | -$6.90M | -$3.34M | -$4.58M | -$6.45M | -$4.81M | -106.8% |
| Net income to common | -$6.90M | -$3.12M | -$4.69M | -$6.45M | -$4.81M | -121.2% |
| Basic EPS | -0.58 | — | -0.45 | -0.66 | -0.49 | — |
| Diluted EPS | -0.58 | — | -0.45 | -0.66 | -0.49 | — |
| EBIT | -$6.70M | -$3.12M | -$4.59M | -$6.45M | -$4.82M | -114.8% |
| EBITDA | -$6.68M | -$3.10M | -$4.57M | -$6.44M | -$4.80M | -115.9% |
| Basic shares | 12.05M | — | 10.34M | 10.00M | 9.76M | — |
| Diluted shares | 12.05M | — | 10.34M | 10.00M | 9.76M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.53M | $3.06M | $8.62M | $6.04M | $4.27M | +702.6% |
| Cash & short-term investments | $24.53M | $4.78M | $10.34M | $6.04M | $4.27M | +413.4% |
| Total current assets | $26.47M | $6.08M | $11.50M | $7.99M | $5.75M | +335.4% |
| Property, plant & equipment | $800.00K | $842.00K | $892.00K | $950.00K | $977.00K | -5.0% |
| Total assets | $27.30M | $6.95M | $12.41M | $8.94M | $6.73M | +292.7% |
| Total current liabilities | $6.34M | $3.56M | $8.79M | $3.56M | $2.35M | +77.9% |
| Current debt | — | — | $2.89M | — | — | — |
| Long-term debt | $3.01M | $2.95M | — | — | — | +2.2% |
| Total debt | $3.17M | $3.14M | $3.04M | $185.00K | $227.00K | +0.9% |
| Total liabilities | $9.67M | $6.99M | $10.82M | $7.29M | $5.17M | +38.4% |
| Retained earnings | -$70.40M | -$63.50M | -$60.16M | -$55.58M | -$49.13M | -10.9% |
| Shareholder equity | $17.63M | -$37.00K | $1.76M | $1.80M | $1.70M | +47,743.2% |
| Working capital | $20.13M | $2.52M | $2.71M | $4.43M | $3.40M | +699.9% |
| Net tangible assets | $17.63M | -$37.00K | $1.76M | $1.80M | $1.70M | +47,743.2% |
| Shares issued | 14.90M | 10.77M | 10.54M | 10.14M | 9.93M | +38.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$6.90M | -$3.34M | -$4.59M | -$6.46M | -$4.82M | — | -106.8% |
| Depreciation & amortisation | $18.00K | $24.00K | $16.00K | $16.00K | $17.00K | — | -25.0% |
| Stock-based compensation | $1.08M | $948.00K | $999.00K | $890.00K | $956.00K | — | +13.6% |
| Change in working capital | $508.00K | -$1.09M | $1.40M | $706.00K | $455.00K | — | +146.7% |
| Operating cash flow | -$4.57M | -$6.03M | -$3.85M | -$3.75M | -$4.32M | — | +24.3% |
| Capital expenditure | -$25.00K | — | -$13.00K | — | — | -$5.00K | — |
| Investing cash flow | -$25.00K | $0 | -$13.00K | -$46.00K | $0 | — | — |
| Financing cash flow | $26.06M | $481.00K | $6.44M | $5.57M | $4.92M | — | +5,317.3% |
| Free cash flow | -$4.59M | -$6.03M | -$3.86M | -$3.80M | -$4.32M | — | +23.9% |
| End cash position | $24.53M | $3.06M | $8.62M | $6.04M | $4.27M | — | +702.6% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.35 | -0.52 | -49.7% |
| Mar 2026 | -0.44 | -0.53 | -19.8% |
| Dec 2025 | -0.50 | -0.31 | +38.0% |
| Sep 2025 | -0.53 | -0.51 | +3.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.35 | 1 | $0 | 0.0% |
| Next quarter | -0.30 | 1 | $0 | 0.0% |
| Current year | -1.41 | 1 | $0 | -100.0% |
| Next year | -1.05 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$9.50
High target$11.00
Low target$8.00
Implied upside239.29%
Analyst count2
ConsensusSTRONG BUY
Strong buy / Buy0 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders50.75%
Held by institutions5.55%
Institutions holding31
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.76
+1.34% from price
SMA 20
2.45
+16.93% from price
SMA 50
2.18
+31.60% from price
SMA 100
2.02
+38.29% from price
SMA 200
2.36
+21.77% from price
EMA 12
2.65
+5.63% from price
EMA 26
2.46
+14.00% from price
EMA 50
2.28
+22.93% from price
RSI (14)
67.1
Neutral
MACD (12,26,9)
0.19
Hist 0.02
ATR (14)
0.22
7.59% of price
Realised vol 30D
66.5%
Annualised
Bollinger upper
3.11
20, 2σ
Bollinger lower
1.80
20, 2σ
50 / 200 cross
Death
2.18 vs 2.36
Trend bias
Above 200
+21.77%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.36
More volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
66.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-77.3%
Peak to trough
Max drawdown 5Y
-97.0%
Peak to trough
ATR 14
0.22
7.59% of price
Beta (reported)
-0.00
5Y monthly, from filing
Short interest
Shares short
222.92K
Prior 285.43K
Change vs prior
-21.9%
Shorts covering
% of float
1.94%
Normal
% of shares out
1.49%
Against total outstanding
Days to cover
5.7
Crowded exit
Float
11.15M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 1, 26 | BTIG | INITIATED | — | Buy |
| Aug 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 14, 25 | HC Wainwright & Co. | INITIATED | — | Buy |
| Mar 11, 25 | Jones Trading | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split28:1000
Split dateMar 15, 2024
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-23
Corporate Changes & Voting Matters
8-K · 2026-07-22
Corporate Changes & Voting Matters
8-K · 2026-06-24
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-06-01
Offering Registrations
S-3 · 2026-05-22
Corporate Changes & Voting Matters
8-K · 2026-05-14
Proxy Statements
DEFA14A · 2026-04-28
Headlines
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · 10d ago
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire · 30d ago
Serina Completes Enrollment, Dosing in First Cohort of Phase 1b Trial in Parkinson's Disease
MT Newswires · 31d ago
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
GlobeNewswire · 31d ago
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
GlobeNewswire · 32d ago
Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease
MT Newswires · 45d ago
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
GlobeNewswire · 45d ago
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
GlobeNewswire · 54d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.